Sentiment Summary
Recent Events
Ex-dividend date for the final dividend of HK$0.0418 per share for the fiscal year ended December 31, 2025, on 2026-06-29; a 10% price impact is estimated due to the accompanying shareholder return plan, scheduled.
The ex-dividend date for the final 2025 dividend of HK$0.16 per share on 2026-06-29 is scheduled. This is estimated to have a ≥1% price impact due to standard dividend adjustments.
Final dividend ex-date for June 22, 2026, with a payment of HKD 0.13577 per share. Low impact estimated as dividend yield is typically within a small percentage range, scheduled.
The 2025 Annual General Meeting (AGM) is scheduled for May 29, 2026, to approve the annual report, profit distribution plan, and board appointments. A price impact of ≥1% is estimated as the meeting will formalize dividend payments and strategic direction scheduled.
Twist Bioscience will host an Investor Day for analysts and institutional investors on May 21, 2026, featuring facility tours and presentations on strategic initiatives and growth opportunities; low importance is estimated as investor days typically provide strategic updates rather than immediate material financial shifts, scheduled.
Adjustment of the conversion price for €1.5 billion convertible bonds from HKD 101.13 to HKD 99.80, effective May 19, 2026, following the final dividend payment, scheduled. Low importance is estimated as this is a technical adjustment.
A briefing session for Q1 2026 earnings on May 19, 2026. Low impact estimated as the primary financial data was already released, scheduled.
Ex-dividend date on May 15, 2026, for the final dividend of HKD 1.08 per share for the year ended December 31, 2025. The dividend was approved at the AGM on May 12, 2026, scheduled. Low importance is estimated as the dividend amount is consistent with previous announcements.
The final dividend for FY2025 of RMB 15.7927 per 10 shares will trade ex-dividend on May 13, 2026. Low importance is estimated as the ex-dividend price adjustment is typically around 1-2%, scheduled.
On 2026-05-12, announced a global strategic collaboration and license agreement with Bristol-Myers Squibb (BMY) covering 13 early-stage programs in oncology, hematology, and immunology with potential milestones of $15.2 billion; this massive deal is estimated to have a >10% price impact.
The company's actual controllers, Chairman Ye Xiaoping and Director Cao Xiaochun, were placed under investigation by the CSRC on May 12, 2026, for suspected information disclosure violations, which is estimated to have a price impact of over 10% due to management risk; expected.
Genscript made a voluntary announcement regarding the Q1 2026 financial results of its associate company, Legend Biotech, which were filed on May 12, 2026; medium importance reflects the impact of a major associate's performance on the company's valuation.
The Board of Directors announced on May 12, 2026, the authorization of a share repurchase program of up to US$1.0 billion from the open market over a 48-month period, stating it demonstrates confidence in the company's long-term outlook.
Announced Q1 2026 results on May 12, 2026, with revenue of RMB 19.47 billion (+17.0% YoY) and Non-IFRS net profit of RMB 1.87 billion (+6.0% YoY).
Announced on May 11, 2026, the completion of the acquisition of a controlling 67.88% stake in Vietnamese pharmaceutical company Imexpharm Corporation, marking a significant expansion into the Southeast Asian market.
Subsidiary Henlius received US FDA approval to conduct a Phase I clinical trial for HLX05-N, a biosimilar of Cetuximab Injection, for metastatic colorectal cancer; 1-2% price impact estimated due to early-stage clinical progress expected.
Announced on 2026-05-10 that China's NMPA granted a third Breakthrough Therapy Designation (BTD) for IBI363; Medium importance estimated due to expedited regulatory path.
Subsidiary Henlius received European Commission approval for two new indications for its anti-PD-1 mAb Serplulimab (Hetronifly®) in esophageal and lung cancers; 5-7% price impact estimated due to market expansion expected.
The company's self-developed B7-H3 targeted antibody-drug conjugate (ADC), HS-20093, was granted Breakthrough Therapy Designation by China's NMPA for treating esophageal squamous cell carcinoma on May 9, 2026, with the announcement made on May 11, 2026.
Announced on 2026-05-08 that China's NMPA approved the Mazdutide pre-filled multi-dose pen; Medium importance estimated due to enhanced product convenience.
On 2026-05-08, announced clinical trial approval notices from China's NMPA for five drugs, including HRS-6093 tablets and Injectable SHR-1826; these regulatory approvals are estimated to have a >1% price impact.
Proposal for the adoption of the 2026 Equity Incentive Plan by the Board of Directors on May 8, 2026; Low importance as a standard corporate procedure scheduled
Reported Q1 2026 total revenue of $301.7 million, an increase of 48% year-over-year, beating estimates. However, EPS of -$0.85 missed forecasts. The company raised its full-year 2026 revenue guidance to $1.30-$1.32 billion. High impact estimated due to significant revenue growth and guidance raise, expected.
Natera announced Q1 2026 results with revenue of $696.6 million, up 38.8% year-over-year and beating expectations. However, the net loss per share was -$0.60, wider than the -$0.50 in Q1 2025 and missing analyst forecasts. The company raised its full-year 2026 revenue guidance, but the stock dropped over 10% on profitability concerns.
Pacific Biosciences reported Q1 2026 financial results with revenue of $37.2 million, missing analyst estimates, and an adjusted EPS of -$0.12, which beat expectations. The company also narrowed its full-year 2026 revenue guidance to $165M-$175M. The stock declined over 14% the following day.
Reported Q1 2026 financial results with revenue of $216.2 million (a 79% YoY increase) and a net loss of $0.5 million ($0.00 EPS), significantly beating analyst expectations. The company also reaffirmed its full-year 2026 revenue guidance. (Estimated medium impact due to significant earnings beat.)
Reported Q1 2026 financial results on May 7, 2026, with revenue of $150.8 million (-3% YoY) and a net loss of $13.5 million. The stock declined over 9% following the release, despite beating analyst estimates.